T2 Biosystems, Inc.
TTOO · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $7,193 | $22,305 | $28,058 | $18,130 |
| % Growth | -67.8% | -20.5% | 54.8% | – |
| Cost of Goods Sold | $15,363 | $21,139 | $20,703 | $21,280 |
| Gross Profit | -$8,170 | $1,166 | $7,355 | -$3,150 |
| % Margin | -113.6% | 5.2% | 26.2% | -17.4% |
| R&D Expenses | $14,153 | $25,932 | $21,801 | $16,919 |
| G&A Expenses | $0 | $30,644 | $0 | $0 |
| SG&A Expenses | $24,830 | $30,744 | $28,527 | $21,287 |
| Sales & Mktg Exp. | $0 | $100 | $0 | $0 |
| Other Operating Expenses | $2,511 | $0 | $0 | $0 |
| Operating Expenses | $41,494 | $56,676 | $50,328 | $38,206 |
| Operating Income | -$49,664 | -$54,045 | -$42,973 | -$41,356 |
| % Margin | -690.4% | -242.3% | -153.2% | -228.1% |
| Other Income/Exp. Net | -$413 | -$6,807 | -$6,268 | -$5,442 |
| Pre-Tax Income | -$50,077 | -$62,003 | -$49,241 | -$46,798 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$50,077 | -$62,003 | -$49,241 | -$46,798 |
| % Margin | -696.2% | -278% | -175.5% | -258.1% |
| EPS | -19.19 | -1,222.14 | -1,549.82 | -1,928.54 |
| % Growth | 98.4% | 21.1% | 19.6% | – |
| EPS Diluted | -19.19 | -1,222.14 | -1,549.82 | -1,928.54 |
| Weighted Avg Shares Out | 2,610 | 51 | 32 | 24 |
| Weighted Avg Shares Out Dil | 2,610 | 51 | 32 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $112 | $0 |
| Interest Expense | $5,343 | $6,084 | $7,596 | $5,504 |
| Depreciation & Amortization | $859 | $1,047 | $2,538 | $3,156 |
| EBITDA | -$43,875 | -$54,872 | -$41,127 | -$36,709 |
| % Margin | -610% | -246% | -146.6% | -202.5% |